Last reviewed · How we verify
HyperAcute-Pancreatic Cancer Vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
HyperAcute-Pancreatic Cancer Vaccine (HyperAcute-Pancreatic Cancer Vaccine) — NewLink Genetics Corporation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HyperAcute-Pancreatic Cancer Vaccine TARGET | HyperAcute-Pancreatic Cancer Vaccine | NewLink Genetics Corporation | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HyperAcute-Pancreatic Cancer Vaccine CI watch — RSS
- HyperAcute-Pancreatic Cancer Vaccine CI watch — Atom
- HyperAcute-Pancreatic Cancer Vaccine CI watch — JSON
- HyperAcute-Pancreatic Cancer Vaccine alone — RSS
Cite this brief
Drug Landscape (2026). HyperAcute-Pancreatic Cancer Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/hyperacute-pancreatic-cancer-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab